The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > COLUMN
COLUMN
- Digital and Cultural Transformation in Japanese Pharmaceuticals
August 13, 2021
- How Manufacturers Can Optimize Wholesaler Relationships and Leverage Wholesalers to Support Business Strategy
July 13, 2021
- Does Your Company Want to Increase Its Diversity?
July 5, 2021
- 5 Lessons in 5 Years from Rocking the Bag
June 17, 2021
- Pricing Reform in Japan - How Manufacturers Can Ensure Fair Compensation for Value and Innovation
May 28, 2021
- Set the Stage for an Exceptional Customer Experience
May 21, 2021
- Pricing Reform in Japan: How Must Life Science Companies Evolve?
April 23, 2021
- Do You Attract or Repel Winning Candidates?
April 16, 2021
- The Future of Customer Engagement in Japan’s Life Science Industry: One Year Post-COVID
March 19, 2021
- Bring Your A-Game to Your Next Video Call
March 11, 2021
- What Personal Biases Influence Your Hires?
February 19, 2021
- Is Your Company Culture Being a Victim of COVID-19?
January 8, 2021
- It’s the Everyday Leaders Your Organization Needs
December 11, 2020
- Let’s Be Grateful for the Chaos of the Year That Was
November 18, 2020
- Empower Smarter Decision Making with Big Data
October 23, 2020
- 5 Improvements when Recruiting Female Employees
September 25, 2020
- Think Differently for Post-Pandemic Success
August 14, 2020
- The Crisis That Ignited a Workplace Revolution
July 6, 2020
- Smart Strategies for Building Your Dream Team
March 17, 2020
- A Peek into the Digital Pharmaceutical Industry
November 21, 2019
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…